GlassScriptPhysician profile
Sepideh Saber
NPI 1285917047
$3,041.61
in general payments reported to CMS, 2019-2025
8 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 82% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $549 · 2021: $109 · 2022: $189 · 2023: $21.33 · 2024: $198 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,275 · Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,274.91 |
| Food and Beverage | $789.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $1,898.04 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander, Artoura Breast Tissue Expander |
| Musculoskeletal Transplant Foundation INC. | $479.05 | 2020 | |
| Allergan, INC. | $318.42 | 2020-2022 | |
| Integra Lifesciences Corporation | $166.67 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Amgen INC. | $92.67 | 2019-2020 | |
| Pacira Therapeutics, INC. | $52.12 | 2019 | |
| Checkpoint Surgical, INC | $22.20 | 2020 | |
| Dynasplint Systems INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sepideh Saber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.